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2Abstract
Grading cervical intraepithelial neoplasia (CIN) determines clinical management of women after
abnormal cytology with potential for over-diagnosis and overtreatment. We studied a novel 
biomarker of HPV life-cycle completion (panHPVE4), in combination with the MCM cell-cycle marker
and the p16
INK4a
transformation marker to improve CIN diagnosis and categorization. Scoring these
biomarkers alongside CIN grading by three pathologists was performed on 114 cervical specimens 
with high-risk (HR-) HPV. Inter-observer agreement for histopathology was moderate (kappa (ĸ): 0.43 
for CIN1/negative, 0.54 for CIN2/≤CIN1, and 0.36 for CIN3). Agreement was good or excellent for 
biomarker scoring (E4: ĸ=0.896; 95%CI: 0.763-0.969, p16
INK4a
: ĸ=0.798; 95%CI: 0.712-0.884, MCM: 
ĸ=0.894; 95%CI: n.c.). Biomarker expression was studied by immunofluorescence and 
immunohistochemistry and correlated with 104 final CIN diagnoses following histological review. All
25 histologically negative specimens were p16
INK4a
and panHPVE4 negative although 9 were MCM 
positive. There were variable extents of p16
INK4a
positivity in 11/11 CIN1, and extensive panHPVE4 
staining in 9/11. Ten CIN2 lesions expressed panHPVE4 and p16
INK4a
and 13 CIN2 expressed only 
p16
INK4a
. CIN3 showed extensive p16
INK4a
positivity with no/minimal panHPVE4 staining. PanHPVE4, 
unlike MCM, distinguished CIN1 from negative. PanHPVE4 with p16
INK4a
separated CIN2/3 showing 
only expression of p16
INK4a
indicating transforming HR-HPV E7 expression, from CIN1/2 showing 
completion of HR-HPV life-cycle by E4 expression and variable p16
INK4a
expression. PanHPVE4 and
p16
INK4a
staining are complementary markers that could provide simple, reliable support for
diagnosing CIN. Their value in distinguishing CIN1/2 that supports HR-HPV life cycle completion (and 
which might ultimately regress), from purely transforming CIN2/3 needing treatment warrants 
further research. 
Keywords: Human Papillomavirus, Cervical Intraepithelial Neoplasia, biomarkers, E4, p16
INK4a
, MCM, 
reproducibility
3Introduction
Prevention of cervical cancer based on screening and treatment of cervical intraepithelial neoplasia 
(CIN) has proved highly effective [1-3]. An important part of clinical management of CIN is 
histological grading, distinguishing CIN1 lesions that generally regress from CIN2/3 that are currently 
treated, preferably by excision. Histological diagnosis of CIN is based on subjective interpretation of 
multiple cellular and architectural neoplastic changes. Effects of inflammation, repair, pregnancy and 
atrophy complicate the diagnosis of pre-malignant lesions, and the histological grading of CIN is 
subject to substantial inter- and intra-observer variability [4-6]. CIN2 is the treatment threshold but is 
not very reproducible [7], and is thought to include a mixture of transient human papillomavirus 
(HPV) infections and true cancer precursors [8]. The reproducibility of the diagnosis of CIN1 is also 
very poor. In the ALTS-trial, a quality control panel of pathologists reviewed 2237 colposcopically
directed biopsies diagnosed at the local sites. Only 43% of biopsies initially diagnosed as CIN1 were 
classified as CIN1 after further review with many not considered as CIN at all [9]. Overall, although 
CIN3 is always considered a true cancer precursor requiring treatment, important clinical decisions 
based on diagnosis of CIN1 and CIN2 are made on poorly reproducible criteria, leading to extensive
follow-up and overtreatment of lesions that would spontaneously regress [10, 11]. In particular it has 
been suggested that CIN2 in young women should not always be treated by excision [12].
Based on understanding of HPV gene expression during productive HPV infection and in neoplasia 
[13-18], several molecular and immunohistochemical biomarkers have been proposed for objective 
grading of CIN lesions. The two most studied are p16
INK4a
and the proliferation marker ki-67. Over-
expression of p16
INK4a 
is caused by up-regulated expression of high-risk (HR)-HPV oncogene E7, and
diffuse p16
INK4a
expression is widely used as a biomarker for HPV induced high-grade (HG)-CIN [19-
21]. A recent systematic review and meta-analysis showed that p16
INK4a
immunostaining correlates 
with the severity of cytological and histological abnormalities [22]. One limitation is that diffuse basal
4and parabasal expression is seen in some lesions that are histologically typical CIN1 and management 
of these is unclear.
Minichromosome maintenance (MCM) proteins are DNA helicases that are essential for genomic 
DNA replication and restrict replication to once per cell cycle [23]. Several studies have shown MCM 
to be a proliferation marker [24-27] similar in expression to ki-67 [28-30], which is used widely in the 
diagnosis of CIN, but is not a specific marker of HR-HPV [31-33]. In normal squamous epithelium 
MCM staining is limited to the basal and immediate parabasal cell layers. In contrast, MCM is 
expressed in the upper two-thirds of the epithelium in HG-CIN [34].
HPV E4 protein is expressed in infected squamous cells supporting viral genome amplification [35]. 
E4 is only expressed in terminally differentiated squamous cells of the intermediate or superficial cell 
layers of the infected epithelium [36]. With increasing precancerous grade cell differentiation is lost. 
As a result, transforming HPV infections fail to express the differentiation dependent E4 protein. 
Therefore, E4 has been suggested as a marker of the onset of the productive stage in the viral life 
cycle and low-grade lesions [37, 38]. Recently, a mouse monoclonal antibody against the E4 protein 
of 15 HR-HPV types (panHPVE4) has been developed, and we investigated the potential clinical 
application of this antibody using immunofluorescence and immunohistochemistry. For our initial 
studies, we used immunofluorescence microscopy to facilitate visualization of multiple markers in 
the same tissue section, followed by hematoxylin and eosin staining to confirm routine pathological 
diagnosis. In clinical practice, biomarker detection will be carried out by immunohistochemistry (IHC) 
and we show that this performs well for the visualization of E4.
The objective of this project was to study the expression patterns of panHPVE4, p16
INK4a
and MCM in 
relation to the classification of routine biopsy specimens with different histological grades of cervical 
lesions. The study aimed to investigate whether combining the immunohistochemical biomarker 
5panHPVE4 with p16
INK4a
and/or MCM could provide a more objective and reproducible clinico-
pathological classification of cervical precancerous lesions related to current concepts of the biology 
and natural history of HPV infection than simple histological grading of CIN or use of p16
INK4a
alone.
Such a classification could offer a more standardized system of grading, and describe more simply 
the complex nature of lesions within each CIN grade. This could provide the basis for further 
investigations aimed at predicting the likely prognosis of different cervical lesions and identifying 
appropriate management.
6Materials and Methods
Study population
Loop electrosurgical excision procedure (LEEP) and hysterectomy specimens from women treated for 
CIN at the Jagiellonian University Medical College, Krakow, Poland and cervical biopsy specimens of 
women obtained during colposcopy at the Gynaecological outpatient clinic of Hospital Clínic, 
Barcelona, Spain and Reinier de Graaf Groep, Voorburg, the Netherlands were enrolled in this study
[39].
Histological diagnosis
Serial paraffin sections were obtained from formalin-fixed and paraffin-embedded (FFPE) histological 
specimens. Three pathologists independently classified all haematoxylin and eosin (H&E) sections as 
negative, CIN1, CIN2 or CIN3. The CIN classification was used in order to permit exploration of the
biomarker pattern seen in CIN2 and the possibility of further study in relation to controversies over 
the outcome of CIN1 and CIN2. It is acknowledged that the LAST guidelines indicate a two-tier 
classification in which CIN2 and 3 are combined as high-grade precancer for safe clinical practice [40]. 
Only specimens that were adequate for grading according to the pathologists were included. The
pathologists were blinded to the HPV status and biomarker results. Specimens with total (3/3 
pathologists) and partial (2/3 pathologists) agreement on histological diagnosis were combined into a 
consensus diagnosis group. Specimens showing discrepant results when the p16
INK4a
and histological 
diagnosis were compared, were subjected to additional histological review. As advocated by the LAST 
guidelines [40] a final diagnosis was made based on further pathological review with knowledge of 
the consensus diagnosis and the p16
INK4a
immunohistochemistry results.
HPV detection
DNA from all specimens was isolated by a proteinase K procedure as described previously [41] and 
HPV DNA detection and genotyping was performed with the SPF10-PCR-DEIA-LiPA25 system (SPF10
7HPV LiPA25 version 1; Labo Bio-Medical Products, Rijswijk, The Netherlands) as described elsewhere 
[42, 43]. DEIA is an ELISA-based hybridization assay detecting at least 54 HPV types using a cocktail of 
9 different probes. DEIA positive amplimers were analysed by LiPA25. The LiPA25 can identify 25 HPV 
genotypes (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 
and 74) by reverse hybridization on a line probe assay. 
DEIA-negative samples were spiked with HPV16 DNA and analysed with type specific PCR to exclude 
inhibition [44] and if necessary the PCR and DEIA were repeated on a 1/10 diluted sample. With this 
an additional 5 samples became HPV positive. Each run contained negative and positive controls. 
Contamination or failure of analyses was not encountered. No additional type-specific testing was 
done.
PanHPVE4 antibody development and validation
Purified maltose binding protein (MBP)-HPV18 E1^E4 fusion proteins were generated according to 
the manufacturer’s instructions (New England Biolabs, Beverly, USA). HPV18 E1^E4-MBP fusion 
proteins were used to immunize female BALB/c mice. Standard enzyme-linked immunosorbent assay 
(ELISA) was used to select the specific monoclonal antibody (mAb). The ability of this mAb, FH1.1, to 
detect HPV E1^E4 protein of different HPV types was tested with MBP-E4 fusion proteins prepared 
from a panel of 10 HPV types (HPV16, 18, 31, 33, 35, 39, 45, 52, 58 and 59) by ELISA and western 
blotting, and by rafts from NIKS cell lines containing HPV16, 18, 31, 45 and 58 [38]. The FH1.1 mAb 
was reactive to all these E4 proteins tested by ELISA, western blot analyses and in the HPV-containing 
rafts. Furthermore, the FH1.1 mAb was assessed on biopsies from cervical lesions containing HPV33, 
35, 39, 51, 52, 53, 56, 66, 67 or 70. The FH1.1 mAb stained positively to E4 proteins of all these HPV 
types with comparable signal strength. The newly generated panHPVE4 mAb FH1.1 is thus capable of 
detecting at least 16 HR-HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67 and 70
(Zhonglin Wu, National Institute for Medical Research, London, UK - manuscript in preparation). It is 
anticipated that DDL Diagnostic Laboratory will distribute the validated panHPVE4 mAb (FH1.1). In 
8the first instance, enquiries should be made either to John Doorbar (jd121@cam.ac.uk) or Wim Quint 
(wim.quint@ddl.nl).
Immunofluorescence
Four-micrometer (μm) thick paraffin sections were cut, slides were dried overnight at 37˚C, 
deparaffinised in xylene and rehydrated in a descending alcohol series. For epitope retrieval, slides 
were autoclaved in solution D pH6.0 (Dako, Glostrup, Denmark) for 2 min at 121˚C. The primary 
antibodies against E4 (panHPVE4: FH1.1) and MCM (Abcam, Cambridge, UK) were applied 1:100, and 
incubated overnight at 4°C. Visualization was performed with 150-fold diluted Alexa-488 (green) 
conjugated anti-mouse secondary antibody against E4 and Alexa-594 (red) conjugated anti-rabbit 
secondary antibody against MCM (both Invitrogen, Paisley, UK). Nuclear counterstaining was 
performed with DAPI (blue) (Sigma, St-Louis, MO, USA).
Immunohistochemistry
P16
INK4a
staining was performed on one 4 μm FFPE-section using heat-induced epitope retrieval with 
citrate buffer (Dako) and a primary mouse monoclonal antibody anti-p16
INK4a
clone JC8 (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA). Reactivity was visualized using the EnVision™ Detection 
System (Dako) for the biopsies and 3-amino-9-ethylcarbazol (AEC, Sigma, St-Louis, MO, USA) for the 
LEEP and hysterectomy specimens. A subset of 48 slides was also stained with the panHPVE4 mAb 
FH1.1 antibody using immunohistochemistry according to the above protocol to allow comparison of 
immunofluorescence with immunohistochemistry.  
Quantification of immunohistochemical results
PanHPVE4 immunoreactivity was scored as (1) negative, (2) superficial - restricted to the upper 
quarter of the epithelium, (3) extensive - upper half of the epithelium or more.
9P16
IKN4a
immunostaining was classified as (1) no or focal p16
IKN4a
positivity, (2) diffuse p16
IKN4a
staining 
restricted to the lower third of the epithelium, (3) diffuse p16
IKN4a
positivity more than a third of the 
epithelium including full thickness staining.
MCM score was classified as (1) basal and parabasal staining only, (2) diffuse staining restricted to 
the lower third of the epithelium, (3) diffuse MCM positivity more than a third of the epithelium
including diffuse full thickness staining. 
Scoring was based on the highest category present in a specimen.
A subset of lesional areas (n=102) was scored by two of the researchers (HG and RvB). Discordant 
scorings were reviewed with an expert pathologist (DJ) and final scoring was determined in 
consultation. The remaining lesions were scored individually by HG and RvB.
Data and statistical analyses
We excluded cases with HPV types 6, 43 or 68/73, because the panHPVE4 antibody is not validated 
for these types. Quadratic weighted kappa statistics were used to assess agreement on the four 
possible histological diagnoses between the pathologists and for the p16
INK4a
and MCM scoring. 
Unweighted kappa-values were calculated for dichotomized categories and for the panHPVE4 
scoring. Strength of agreement was judged according to Landis and Koch [45]: kappa (ĸ)<0 as no 
agreement, 0-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 
0.81-1 as almost perfect agreement. A pathologist annotated regions of interest on the H&E slides. 
The three pathologists also independently graded all regions. These diagnoses were used to correlate 
the extent of the E4 expression to the CIN grade. The Chi-square test was used to analyze the 
association between panHPVE4 positivity and lesion grade and to calculate the relation between the 
extension of the panHPVE4 expression and the CIN-grade. P-values below 0.05 were considered 
significant. Immunostaining results of p16
INK4a
, panHPVE4 and MCM were related to the consensus 
and final diagnoses.
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Results
HPV detection 
Initially, 114 specimens were included in the study from patients with a median age of 39 years 
(range: 19-80 years). HPV was detected in 100 (88%) specimens, with 14 (12%) of the specimens 
being HPV negative. HPV types 16, 18, 31, 33, 35, 39, 51, 52, 53, 56, 58, 59 and 66 were detected
amongst the samples analyzed. The HPV type distribution by diagnosis is shown in Supplemental 
Digital Content 1. HPV16 was the most prevalent HPV type (n=44; 39%), followed by HPV33 (n=16; 
14%), HPV52 (n=11; 10%), and HPV31 (n=9; 8%). Multiple HPV infections were apparent in 11/100
(11%) of the HPV positive biopsies. HR-HPV was detected in 59/61 (94.3%) of women diagnosed with 
CIN2 or 3. Twelve of the HPV negative specimens were histologically completely negative and two 
HPV negative specimens were CIN3 at final consensus diagnosis.
Interobserver agreement on histological diagnoses
A total of 104 specimens with a consensus diagnosis were included in our analyses. In 53 specimens,
the pathologist panel achieved total agreement with regard to the diagnosis of the worst CIN grade,
whereas in 51 specimens, the diagnosis was based on agreement of 2/3 pathologists. Ten specimens 
were excluded because there was total disagreement amongst the pathologist panel. Total 
pathologist agreement was achieved for only two CIN2 specimens. 
CIN grading showed substantial inter-observer variation. The mean inter-observer agreement ranged 
from fair (ĸ=0.357 for diagnosis of CIN3) to moderate (ĸ=0.536 for CIN2 versus CIN1 or less) with an 
overall weighted ĸ-value of 0.568 (Table 1). 
Agreement in biomarker scoring
There was excellent agreement in panHPVE4 immunofluorescence scoring between the two
researchers (ĸ=0.896; 95%CI: 0.763-0.969) with 93.8% concordance. The concordance in p16
INK4a
11
scoring was 72.9%, with good agreement above chance (ĸ=0.798; 95%CI: 0.712-0.884) and a 
concordance of 81.0% in scoring of MCM with ĸ=0.894 (95%CI: n.c.) (Table 2).
As shown in Figure 1, the pattern of E4 expression observed in the different samples was broadly 
similar, irrespective of whether immunofluorescence of immunohostochemical detection was used 
for visualization, which is of particular importance given the possible utility of E4 antibodies for 
routine diagnostic purposes. A 100% agreement was observed between the two researchers on the 
subset of specimens stained using panHPVE4 immunohistochemistry, with a ĸ-value of 0.898 (95%CI: 
0.807-0.989) on the extent of the staining.
Biomarker expression patterns and HPV status in specimens with consensus diagnosis
Table 3 shows the biomarker expression patterns and HPV positivity rates in relation to the 
consensus diagnosis. All CIN lesions were HPV positive, with the exception of two of the CIN3 lesions,
and 12/26 histologically negative specimens, which were also HPV negative.
Of 26 specimens judged to be histologically negative for dysplasia, 23 (88%) were negative for 
p16
INK4a
and panHPVE4 (Figure 2). Three histologically negative specimens showed regions of 
extensive p16
INK4a
and MCM staining but were negative for panHPVE4. On re-examination, these 
were recognized as small CIN3 lesions that had been missed during the initial assessment. In 
addition, 8 specimens were MCM positive but negative for both p16
INK4a
and panHPVE4 and were not 
reclassified as CIN. Eight out of 15 MCM negative specimens were HPV positive by PCR.
Fifteen of the 17 CIN1 specimens were p16
INK4a
positive, of which three had diffuse lower third 
p16
INK4a
staining. Twelve showed diffuse p16
INK4a
staining, which extended through more than one-
third of the epithelium. Four of these 12 were subsequently reclassified as CIN2 after histological 
review. Two of the 17 CIN1 specimens were p16
INK4a
and panHPVE4 negative and were downgraded 
to negative for CIN on review. One of these two specimens was MCM positive and most likely 
represents normal metaplasia.  
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All CIN2 and CIN3 specimens showed extensive p16
INK4a
and a corresponding pattern of MCM staining 
which extended through more than one-third of the epithelium. Nine CIN2 were panHPVE4 positive 
(extensive or superficial) and 10 were negative, compared with 8 CIN3 which showed only focal 
panHPVE4 positivity in a few superficial cells, and 33 which were panHPVE4 negative. One CIN3 
specimen showed more extensive panHPVE4 positivity of the upper half (extensive).
Biomarker expression patterns and HPV status in relation to final diagnosis
Table 4 shows the expression patterns and HPV status of p16
INK4a
and panHPVE4 staining in relation 
to the final diagnoses after additional review. Four patterns of staining were identified.
NEGATIVE: All 25 specimens that were histologically negative on final diagnosis were negative for 
p16
INK4a
and panHPVE4 (see Figure 2), although 9 were MCM positive.
PRODUCTIVE: This pattern showed strongly positive panHPVE4 staining and diffuse p16
INK4a
staining 
that was restricted to the lower third of the epithelium. Such staining was seen in 2/11 CIN1. One 
CIN1 showed only lower-third p16
INK4a
staining with no panHPVE4 staining. Figure 3 shows the 
biomarker expression pattern typical of productive CIN1 lesion.
INTERMEDIATE: Seven of the 11 CIN1 showed diffuse p16
INK4a
staining of two-thirds or more of the 
epithelium with extensive panHPVE4 positivity. A similar pattern was seen in 6/23 CIN2 cases that 
were panHPVE4 positive. One out of 45 CIN3 cases showed this pattern (see Figure 4).
TRANSFORMING: This pattern showed limited or absent E4 expression, with p16
INK4a
expression in 
two-thirds of the epithelium or full thickness. This was seen in 44/45 CIN3 lesions, of which only 8 
showed any panHPVE4. In such lesions, staining was limited to one or two cell layers or even to just a 
few cells. Absence of E4 expression was seen in 13/23 CIN2 lesions. This pattern was seen in only one 
of 11 CIN1 lesions. An example of a typical biomarker expression pattern of CIN3 specimens is shown 
in Figure 5, with the broad patterns seen in different lesions being shown in Figure 6.
The extent of E4 expression declines with lesion grade
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Interestingly, there was a significant difference in E4 positivity between CIN grades. Nine of the 11
final CIN1 cases were E4 positive (82%), 10/23 CIN2 (43%) and 9/45 CIN3 (20%) (p<0.0001). For 
panHPVE4 positive cases, E4 expression was limited to the upper quarter of the epithelium in 8/9
(89%) CIN3 cases, in 4/10 (40%) CIN2 cases, and in 0/9 (0%) CIN1 cases. Of the panHPVE4 positive 
CIN1 cases, 6 (67%) showed E4 occupying half the depth of the epithelium and in 3 (33%) E4 was 
even more extensive. Overall, the extent of E4 expression declined with increasing lesion grade 
(p=0.001). 
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Discussion
Our findings show that the scoring of biomarkers panHPVE4, MCM and p16
INK4a
can be reproducibly 
achieved, and that consistent expression patterns of panHPVE4 and p16
INK4a
can be defined and 
related to grade of CIN in lesions associated with HR-HPV. Specimens that were finally agreed to be
normal showed no expression of either panHPVE4 or p16
INK4a
, although MCM was sometimes
positive. These data show that panE4 expression can be detected by immunofluorescence and IHC,
and suggest that a combination of panHPVE4 and p16
INK4a
, detected using standard IHC techniques in 
routine clinical practice, may be particularly useful in distinguishing between normal events (such as 
metaplasia or inflammation), and true HPV-associated CIN. In CIN caused by HPV, the extent of 
panHPVE4 and p
16INK4a
expression generally showed an inverse correlation. When CIN1 was agreed,
there was almost always extensive panHPVE4-positivity in the upper epithelial layers, and either 
lower-third or more extensive p16
INK4a 
staining. CIN2 typically showed extensive p16
INK4a
staining and 
was divided into two categories, which could be defined by the presence or absence of panHPVE4 
expression. For hematoxylin and eosin diagnosis there was greatest disagreement (kappa= 0.36) over 
CIN3, especially versus CIN2. Most (80%) of CIN3 cases were completely panHPVE4 negative and 
when E4 was detected it was mostly confined to a few superficial cells. All CIN3 cases showed 
diffusely full thickness p16
INK4a
staining. P16
INK4a
biomarker patterns also identified some difficult and 
small high-grade lesions that were missed even by multiple experienced pathologists, but confirmed 
on pathological review. The combination of panHPVE4 and p16
INK4a
proved to be most useful in 
separating normal and CIN, as increased MCM staining above the basal layer was sometimes seen in 
cervical lesions not considered as CIN on consensus pathological diagnosis. Cell cycle markers such as 
MCM and ki-67 are not specific for dysplasia; they identify also cells proliferating because of 
inflammation, epithelial repair or metaplasia. We do not provide evidence to support the suggestion 
that the distribution of MCM differs importantly in cervical neoplasia from that described for ki-67, 
or suggest it is specific for neoplasia. In other tissues, MCM and ki-67 can give non-identical staining 
patterns, with MCM being proposed as a more sensitive marker of high-grade disease [28, 30].
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The proportion of panHPVE4 positive cases and the extent of panHPVE4 expression decreased 
significantly with increasing lesion-grade, consistent with our previous analysis [38]. This correlates 
with observations in animal models and HPV16-positive biopsies showing loss of E4 with loss of 
surface epithelial differentiation [17, 35].  Many of these previous studies used immunofluorescence 
to visualize protein distributions, but in this study we also applied standard immunohistochemistry
methodologies to 48 of the cases. We found 100% agreement between immunofluoresence and 
immunohistochemical staining for panHPVE4 and p16
INK4a
. Establishing this is of some importance, as 
it suggests that panHPVE4 antibody is suitable for routine immunohistochemistry, in addition to 
research-based studies aimed at understanding disease biology (see Figure 1).
The combination of panHPVE4 biomarker used here with p16
INK4a
offers a reliable, objective approach 
to grading CIN lesions associated with HR-HPV, identifying productive, intermediate and transforming 
lesions, thus adding to the information provided by p16
INK4a
alone. The productive pattern
corresponds closely to the concept of “classical” CIN1 in which the full life-cycle of the virus is 
supported (see Fig. 6), but was seen in only a minority of CIN1 associated with HR-HPV in this study. 
This may be partly because only HR-HPV positive cases with high-grade, low-grade or repeated ASC-
US cytology or being treated for CIN2+ were included. This pattern, however, blends into the 
intermediate pattern of expression, with both more extensive p16
INK4a
positivity and widespread 
panHPVE4 expression seen in most (64%) CIN1 and 26% (6/23) of CIN2. The transforming category,
with no or minimal evidence of a HPV productive infection and panHPVE4 expression, but with 
extensive p16
INK4a
expression, was seen in 44/45 CIN3, in 17/23 CIN2 and one CIN1. These patterns 
therefore confirm that CIN1 and CIN2 are not homogeneous categories, and show that CIN2, 
particularly, is a mixture of lesions.
Strong expression of panHPVE4 in some CIN2 with the intermediate pattern shows that the HR-HPV 
productive cycle has been initiated, with the extensive expression of p16
INK4a
suggesting that this is 
16
combined with an elevated activity of the transforming HR-HPV gene E7.  In this intermediate pattern 
there is substantial overlap between CIN2 and morphological CIN1, with seven CIN1 lesions showing
extensive p16
INK4a
expression whilst also showing strong panHPVE4 staining.
The loss or minimal extent of HR-HPV life cycle completion associated with strong p16
INK4a
staining 
indicating HR-HPV E7 gene activity, was seen in all CIN3 and also 17/23 (74%) CIN2 and one CIN1. 
This clearly indicates that CIN2 is not biologically homogeneous, with some aligning with CIN1 
(intermediate pattern) and some with CIN3 (transforming pattern).
The diagnosis of CIN2 and its distinction from CIN1 and from CIN3 is a well-recognised problem. Our 
finding that the CIN2 category is a mixture of intermediate (productive life-cycle initiating) and 
transforming infections is in line with previous findings that CIN2 is the least reproducible grade of 
CIN [5-7], and with the paper from Castle et al. which suggests CIN2 to be a mixture of transient HPV 
infections and true cancer precursors [8]. This, together with a relatively high rate of regression of 
CIN2 [11, 12] suggests that the biomarkers panHR-HPV E4 and p16
INK4a
in combination could provide 
a reliable basis for separating CIN2 into subcategories and investigating the frequency and natural 
history of these subcategories in relation to age, incident and persistent HPV infection, or other 
molecular markers of neoplastic progression, regression and treatment response which might be 
used to improve patient management. The different biomarker patterns seen in CIN2 contrast with 
the transforming pattern that was always seen in CIN3. CIN1 also was not homogeneous, although 
most of these lesions in “older” women (median age 39 years) were in the intermediate category.  
PanHPVE4 could also contribute to avoiding over-diagnosis of normal epithelial areas as CIN. None of 
the final histologically negative specimens were panHPVE4 positive and both consensus CIN1 lesions 
that were downgraded to normal (Table 3) were also panHPVE4 negative. The markers used in this 
study have a strong rationale for their use, and are based on well-characterized patterns of HPV gene 
expression that have been validated at both the protein and mRNA level [13-18]. The distribution of 
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E6/E7 mRNA in the suprabasal epithelial layers, and the elevation of transcripts that span the E4 
region during productive infection was first observed during the late 1980s and early 1990s [13, 15, 
18]. Although the relatively low levels of the viral early gene products compromises routine detection 
[46], the use of surrogate biomarkers of their presence (such as p16
INK4a
, MCM and ki-67) has gained 
acceptance in recent years. In addition, we now know that the E4 protein has the ability to 
accumulate in the form of amyloid fibres at high levels [47, 48], which allows the protein to be easily 
detected in the upper epithelial layers during productive infection [37, 38].
Follow-up studies are required to identify the risk related to the different biomarker patterns in CIN1 
and CIN2, and to decide on the appropriate treatment or follow-up of lesions that show evidence of
life-cycle completion (productive/intermediate), compared to those expressing only p16
INK4a
as 
evidence that there is only HR-HPV transforming gene activity. Recent guidelines from the USA 
suggest treatment of all p16
INK4a
positive CIN lesions with any suspicion of being high-grade [40]. 
However, a substantial number of CIN1 lesions show p16
INK4a
over-expression [49]. There are several 
studies that show an increased progression risk of p16
INK4a
positive CIN1 [50-54]. Still the majority of 
women did not progress. These published studies however, did not distinguish extent of p16
INK4a
expression or take account of the differences between high-risk and low-risk HPV in relation to 
progression, which makes further study necessary. 
The combination of panHPVE4 and p16
INK4a
provides a simple approach to distinguishing CIN 
associated with HR-HPV from normal and also clearly demonstrates the complexity of CIN1 and CIN2. 
The robust staining obtained with both markers by IHC, further suggests that E4 could be used 
alongside p16
INK4a
during routine analysis and IHC double staining is being developed. CIN1 showed 
both productive, intermediate (mainly) and occasionally transforming patterns. In this study all CIN3 
and half the CIN2 were transforming lesions by panHPVE4 and p16
INK4a
, with the other half of the 
CIN2 being intermediate lesions. Development of IHC double staining is in progress and further 
18
studies are required to understand the biology of these lesion categories, and to investigate whether 
the combination of panHPVE4 and p16
INK4a
can predict progression or regression of lesions and 
provide a basis for refining management decisions about follow-up and treatment of CIN1 and CIN2.
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List of abbreviations
CIN Cervical intraepithelial neoplasia
DEIA DNA enzyme immuno assay
FFPE Formalin fixed paraffin embedded
H&E Hematoxylin and Eosin
HPV Human papillomavirus
HR-HPV High-risk Human papillomavirus
HG-CIN High-grade cervical intraepithelial neoplasia
IF Immunofluorescence
IHC Immunohistochemistry
LEEP Loop electrosurgical excision procedure
LiPA Line probe assay
MCM Minichromosome maintenance protein
PCR Polymerase chain reaction
SPF Short PCR fragment
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Figure legends
Figure 1. Comparison of detection of expression of panHPVE4 by immunofluorescence (IF; in green; 
nuclei counterstained using DAPI, in blue) (B, E) and immunohistochemistry (in brown) (C, F) in a 
productive CIN1 lesion.  Images A, B, and C were captured at higher magnification than those shown 
in D, E, and Fto illustrate the wide distribution of HPVE4  that can sometimes be seen in low-grade 
CIN1 lesions.
Figure 2. Cervical squamous epithelium, negative for HPV DNA and by consensus histology (A): there 
is no panHPVE4 detected by IF and only parabasal MCM staining (in red; nuclei counterstained using 
DAPI, in blue) (B), and absent p16
INK4a
by IHC (C).
Figure 3. CIN1 lesion by consensus histology (A): strongly positive for panHPVE4 by IF (in green), 
widespread MCM staining (in red; nuclei counterstained using DAPI, in blue) (B), and p16
INK4a
staining 
of the lower third of the epithelium by IHC (C).
Figure 4. CIN2 lesion by consensus histology (A): panHPVE4 staining of upper quarter of the 
epithelium by IF (green; MCM red; DAPI blue) (B) and extensive p16
INK4a
staining by IHC (brown) (C).
Figure 5. CIN3 lesion by consensus histology (A): nopanHPVE4 expression by IF (green) with full 
thickness MCM (red; DAPI blue) (B) and p16
INK4a
expression by IHC (brown) (C).
Figure 6. Schematic diagram summarizing the panHPVE4, p16
INK4a
and MCM biomarker expression 
patterns in relation to histological diagnoses by CIN classification.
Cells expressing E4 are shown in green, while those expressing p16 are shown in brown. Cells expressing MCM 
are indicated by the presence of red nuclei. Normal squamous epithelium does not express p16
INK4a
or E4 and 
has only (para)basal MCM staining. The productive pattern is extensively positive for E4 with widespread MCM 
staining, and p16
INK4a
staining typically restricted to the lower third of the epithelium. The intermediate pattern 
shows E4 staining of upper quarter or less of the epithelium and p16
INK4a
in lower two-thirds of epithelium. The 
transforming pattern shows limited or no E4 expression, with p16
INK4a
expression in two-thirds or more of the 
epithelium or full thickness.
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1Table 1. Agreement in histological diagnoses between pairs of pathologists
Histological categories Mean kappa value (weighted)
All histological diagnoses 0.568
Mean kappa value (unweighted)
Negative versus ≥CIN1 0.427
≤CIN1 versus CIN2/3 0.536
≤CIN2 versus CIN3 0.357
2Table 2. Agreement in biomarker scoring
Biomarker scoring Kappa values 95% CI
E4 0.896 0.763 - 0.969
p16 0.798 0.712 - 0.884
MCM 0.894 n.c.
3Table 3. Consensus diagnosis in relation to the staining patterns and HPV status
Consensus 
diagnosis n
p16 E4 MCM
HPV status Reviewscore n score n score n
Negative 26
Negative 23 Negative 23
Negative 15 8/15 positive
Lower third 5 2/5 positive
Extensive 3 1/3 positive
Extensive 3 Negative 3 Extensive 3 3/3 positive CIN3
CIN1 17
Negative 2 Negative 2
Negative 1
17/17 positive
Negative
Lower third 1 Negative
Lower third 3
Negative 1 Lower third 1
Extensive 2 Extensive 2
Extensive 12
Negative 4
Extensive 12
3 CIN2
Superficial 1 CIN2
Extensive 7
CIN2 19 Extensive 19
Negative 10
Extensive 19 19/19 positiveSuperficial 3
Extensive 6
CIN3 42 Extensive 42
Negative 33
Extensive 42
31/33 positive
Superficial 8 8/8 positive
Extensive 1 1/1 positive
4Table 4. p16 and panE4 staining in relation to the final histological grade
Final histological grade 
(p16+consensus+review) n
p16 E4
HPV statusscore n score n
Negative 25 Negative 25 Negative 25 13/25 positive
CIN1 11
Lower third 3
Negative 1
11/11 positive
Extensive 2
Extensive 8
Negative 1
Extensive 7
CIN2 23 Extensive 23
Negative 13
23/23 positiveSuperficial 4
Extensive 6
CIN3 45 Extensive 45
Negative 36
43/45 positiveSuperficial 8
Extensive 1
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